Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2010-03-12
2011-10-25
Canella, Karen (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S405000, C530S406000, C530S412000
Reexamination Certificate
active
08044183
ABSTRACT:
The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.
REFERENCES:
patent: 4302386 (1981-11-01), Stevens
patent: 4384995 (1983-05-01), Stevens
patent: 4526716 (1985-07-01), Stevens
patent: 5500354 (1996-03-01), Kitamura et al.
patent: 5593876 (1997-01-01), Stamler et al.
patent: 5888517 (1999-03-01), Forsgren
patent: 5905142 (1999-05-01), Murray
patent: 5922846 (1999-07-01), Cerletti
patent: 5925729 (1999-07-01), Boon et al.
patent: 5942235 (1999-08-01), Paoletti
patent: 6030780 (2000-02-01), Vinkemeier et al.
patent: 6139846 (2000-10-01), Forsgren
patent: 6287569 (2001-09-01), Kipps et al.
patent: 6291430 (2001-09-01), Chaux
patent: 6340461 (2002-01-01), Terman
patent: 6426217 (2002-07-01), Chaux
patent: 6475783 (2002-11-01), Lucas et al.
patent: 6680191 (2004-01-01), Lucas et al.
patent: 6686147 (2004-02-01), Scanlan et al.
patent: 6716809 (2004-04-01), Schultz et al.
patent: 6780407 (2004-08-01), Paoletti et al.
patent: 6982316 (2006-01-01), Scanlan et al.
patent: 7157089 (2007-01-01), Mizzen et al.
patent: 2002/0176865 (2002-11-01), Lucas et al.
patent: 2003/0170256 (2003-09-01), Lucas et al.
patent: 0176493 (1986-04-01), None
patent: WO84/03443 (1984-09-01), None
patent: 365278 (1990-04-01), None
patent: WO91/18926 (1991-12-01), None
patent: WO92/20356 (1992-11-01), None
patent: WO94/00575 (1994-01-01), None
patent: 9405304 (1994-03-01), None
patent: WO 94/05304 (1994-03-01), None
patent: WO94/05304 (1994-03-01), None
patent: WO94/16716 (1994-08-01), None
patent: WO94/23031 (1994-10-01), None
patent: WO95/04542 (1995-02-01), None
patent: WO95/17210 (1995-06-01), None
patent: WO95/20974 (1995-08-01), None
patent: WO95/23874 (1995-09-01), None
patent: WO 96/10413 (1996-04-01), None
patent: WO96/22373 (1996-07-01), None
patent: WO96/10413 (1996-12-01), None
patent: WO97/01574 (1997-01-01), None
patent: WO97/13858 (1997-04-01), None
patent: WO97/46710 (1997-12-01), None
patent: WO98/10780 (1998-03-01), None
patent: WO98/14463 (1998-04-01), None
patent: WO98/20165 (1998-05-01), None
patent: WO98/49184 (1998-11-01), None
patent: WO99/14326 (1999-03-01), None
patent: WO99/40188 (1999-08-01), None
patent: WO99/53095 (1999-10-01), None
Chen et al., Identification of theMAGE-1gene product by monoclonal and polyclonal antibodies, Proc. Natl. Acad. Sci. USA 91:1004-1008 (1994).
Okamoto et al., Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine, Gene Therapy 4:969-976 (1997).
Shaw et al., Immunologic Studies on the Influenza A Virus Nonstructural Protein NS, Journal of Experimental Medicine 156:243-254 (1982).
European Search Report for 05076599.9 dated Oct. 20, 2005.
Hoon et al., Melanoma Patients Immunized with Melanoma Cell Vaccine Induce Antibody Responses to Recombinant MAGE-1 Antigen, The Journalof Immunology 154(2):730-737 (Jan. 1995).
Janson et al., Protein D, an Immunoglobulin D-Binding Protein of Haemophilus influenzae: Cloning, Nucleotide Sequence, and Expression inEscherichia coli, Infection and Immunity, 59(1), 119-125 (1991).
Traversari et al., IFN-y gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer, Gene Therapy, 4:1029-2035 (1997).
Gaugler, Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes, J. Exp. Med. 179:921-930 (1994).
Garcia et al., Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promoter inEscherichia coli, Gene, 43:265-272 (1986).
Houen et al., Conjugation to preactivated proteins using divinylsufone and iodoacetic acid, Journal of Immunological Methods, 181:187-200 (1995).
Valmori et al., Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients, Cancer Research 57:735-741 (1997).
GenBank Accession No. NP—005353.
Carrell et al., Int. J. Cancer, 1996, vol. 67, pp. 417-422.
Kocher et al., Cancer Research, Jun. 1, 1995, vol. 55, pp. 2236-2239.
Maeurer et al., Melanoma Research 1996, vol. 6, pp. 11-24.
Marchand et al , “Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical Report,” European Journal of Cancer (2003) 39:70-77.
Vantomme, et al., Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the ASO2B Adjuvant in Patients with MAGE-3 Positive Tumors, J Immunother (Mar./Apr. 2004)27(2):124-135.
Imai, et al., “Sequence Analysis of the MAGE Gene Family Encoding Human Tumor-Rejection Antigens,” Gene (1995) 160:287-290.
De Plaen et al., Structure Chromosomal Localization and Expression of 12 Genes of the MAGE Family, Immunogenetics (1994) 40:360-369.
Blake et al., International Journal of Peptide and Protein Research, 1992,vol. 40, pp. 62-65 Abtract only.
Reynolds et al. (International Journal of Cancer, 1997, vol. 72, pp. 972-976).
Vidard et al., (Journal of Immunology, 1992, vol. 149, pp. 498-504.
Sato et al., (Clinical Immunology and Immunopathology, 1997, vol. 5, pp. 265-272.
Berd, Proceed Amer Assoc Cancer Research, 1995, vol. 36, pp. 677-678.
Lauritzsen et al. (International Journal of Cancer, 1998, vol. 78, pp. 216-222).
Sarma et al., (Journal of Experimental Medicine, 1999, vol. 189, pp. 811-820.
Ohlen et al., (Journal of Immunology, 2001, vol. 166, pp. 2863-2870).
Antoinia et al. (International Immunology, 1995, vol. 7, pp. 715-725).
Algarra et al (International Journal of Clinical and Laboratory Research, 1997(27): 95-102 (Abstract).
Parmiani et al. (in: Heterogeneity of Cancer Cells, 1993, pp. 105-115.
Bodey et al. (Anticancer Research, Jul.-Aug. 2000, vol. 20, pp. 2665-2676.
Itoh et al., Journal of Biochemistry 1996, vol. 119, pp. 385-390 (Abstract).
Paul, Fundamental Immunology, (text), 1993, pp. 1163-1169.
Apostolopoulos et al (nature Medicine, 1998, vol. 4, pp. 315-320.
Jager et al (PNAS, 2000, vol. 97, pp. 12198-12203).
Semino et al (Journal of Biological Regulators and Homeostatic Agents, 1993, vol. 7 pp. 99-105) (Abstract).
Stedman's Medical Dictionary, 2000, definition of “vaccine”.
Lee et al (Journal of Immunology, 1999, vol. 163 pp. 6292-6300.
Atanackovic et al, PNAS 2008, vol. 105, pp. 1650-1655.
Hofffman et al, International Journal of Cancer, 2005, vol. 115, pp. 98-104.
Van Der Bruggen, Science 254:1643-47 (1991).
Creighton, Trends in Biotechnology (TIBTech) 13:18-23 (1995).
Submission to European Patent Office in International Patent Application PCT/EP00660, dated Mar. 23, 2000, including Appendix 1 (13 pages).
PCT Written Opinion, PCT EP/99/00660, Nov. 26, 1999, 6 pp.
International Preliminary Examination Report, PCT EP/99/00660, 7 pp.
Reply to Communication PCT/IPEA/408, PCT EP/99/00660, Mar. 23, 2000, 3 pp.
Decision to Grant European Patent, EP1053325 (EP99907476), Nov. 24, 2005, 4 pp.
Reply to the Examining Division, EP1053325 (EP99907476), Jul. 23, 2003, 8 pp.
Communication from the Examining Division—Communication pursuant to Article 96(2) EPC, EP1053325, (EP99907476), Oct. 1, 2003, 3 pp.
Communication regarding transmission of the European Search Report, European Search Report and European Search Opinion, EP1659179 (app No. 06075363.9), Dec. 14, 2006, 9 pp total.
Communication from Examining Division, EP1659179 (app No. 06075363.9), Apr. 28, 2008, 4pp.
Reply to Communication from Examining Division, EP1659179 (app No. 06075363.9), Sep. 30, 2008, 2 pp.
Communication from Examining Division, EP1659179 (app No. 06075363.9), Nov. 27, 2009, 3 pp.
Reply to Communication from Examining Division, EP1659178 (app No. 06075362), Sep. 30, 2008, 3 pp.
Communication from Examining Division, EP1659178 (app No. 06075362), Apr. 28, 2008, 5 pp.
Brasseur et al., Letter to the editor, Int. J. Cancer 52 :839-841 (1992).
Brasseur et al., “Expression of MAGE genes in primary and metastatic cutaneous melanoma,” Int. J. Cancer 63 :375-380 (1995).
Chen et al.
Cabezon Silva Teresa
Cohen Joseph
Slaoui Moncef Mohamed
Vinals Bassols Carlota
Canella Karen
GlaxoSmithKline Biologicals S.A.
Kron Eric J.
LandOfFree
Process for the production of immunogenic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the production of immunogenic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the production of immunogenic compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297736